• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is AstraZeneca (LSE:AZN) Fully Priced After Its Recent Oncology Wins?

    Simply Wall St·11/04/2026 15:24:33
    Listen to the news

    AstraZeneca has had a strong run in recent years, helped by a busy oncology pipeline and a string of positive trial readouts, so the live question for you now is whether the current share price lines up with the cash the business is expected to generate. Recent progress in cancer treatments and new approvals has sharpened the focus on what those prospects are actually worth when set against its cash flows.

    • A 64.4% total return over 5 years puts real weight on the issue of whether AstraZeneca’s present valuation is fully explained by its cash generation potential.
    • Recent trial successes and new approvals across oncology, from Enhertu and Tagrisso combinations to new assets like ZEGFROVY, can influence expectations for future cash inflows and the timing of those flows as these therapies move through regulatory and commercial stages.
    • Prefer to judge AstraZeneca on earnings? See what AstraZeneca's 26.0x P/E says about the price.

    The issue now is whether AstraZeneca’s current market price is adequately supported by its cash flows when assessed against an intrinsic value estimate based on the Discounted Cash Flow (DCF) approach.

    If you want to test the same cash flow question you are asking of AstraZeneca across a wider set of oncology focused players, run the 9 healthcare AI stocks.

    Does AstraZeneca Look Undervalued on Cash Flow?

    The Discounted Cash Flow (DCF) model used here projects AstraZeneca’s future free cash flows and then discounts them back to today in US$ terms. On this view, the group moves from last twelve month free cash flow of about US$7.1b to forecast annual cash flows that are growing into the next decade, which is a sizable base for a large pharma business. The DCF projections put AstraZeneca's estimated intrinsic value substantially above the current share price of £137.60.

    The cash flow path implied in the 2 Stage Free Cash Flow to Equity model assumes a period of solid growth followed by a more mature phase. This is consistent with a pipeline that is busy but no longer early stage. The strong Phase III CLARITY-Gastric01 result for sonesitatug vedotin adds another potential oncology cash generator, which helps explain why a cash flow driven model can support an intrinsic value estimate that sits well above where the stock trades today. Find out what AstraZeneca could be worth using our Discounted Cash Flow (DCF) estimate.

    The AstraZeneca Narrative: What Would Justify Today's Price?

    Simply Wall St Narratives pick up where the AstraZeneca valuation puzzle leaves off and spell out which assumptions about future growth, margins and earnings would need to hold for the shares to be worth materially more or materially less than today's price. Instead of just giving a single figure from a ratio or model, they map out the future that number relies on so you can watch how AstraZeneca's actual progress lines up with that path. These are available on Simply Wall St's Community page and give you a structured way to track whether the underlying story behind the valuation stays intact over time.

    Community views on AstraZeneca split between a pipeline driven upside story and a more cautious take on execution risk and rising fixed costs.

    Bull case: 12% undervalued

    "The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular or metabolic therapies, is now underpinned by management's disclosure of 12 programs each with risk adjusted peak sales potential above US$5b and several more in the US$3b to US$5b range..."

    Discover why this Narrative puts AstraZeneca at 12% undervalued.

    Bear case: 18% overvalued

    "Large scale investments in AI enabled discovery and a multi billion dollar capital build out, including a new ADC facility and expanded emerging market manufacturing, increase fixed costs..."

    Explore why this Narrative puts AstraZeneca at 18% overvalued.

    One more AstraZeneca angle worth stressing before you move on

    Beyond the cash flow story and competing narratives, AstraZeneca also has some risk checks that trigger concerns, and those could matter just as much to your thesis. Take a closer look at 1 warning sign before settling on a valuation.